AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02531620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiatry Assessment
Description: Physiatrists are physicians who are medical experts in maximizing a patient's overall ability to function well and live independently. The Investigators are proposing your participation in an initial pilot study in order to test the question as to whether or not participation with a physiatrist and any interventions recommended by said physician would help improve a patient's postoperative recovery.
Study NCT02531620 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine Care
Description: Usual care for your disease process
Study NCT01995227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloVax
Description: Personalized anti-cancer vaccine
Study NCT01995227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRCL
Description: Personalized anti-cancer vaccine
Study NCT01995227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: ID injections IV infusion
Study NCT02793245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaire on their main characteristics : age, gender, height, weight, smoking
Study NCT02793245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simplified pulmonary function test
Study NCT02817867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Transcranial direct current stimulation (tDCS)
Study NCT02817867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: Transcranial magnetic stimulation
Study NCT02817867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS + TMS
Description: Association between tDCS and TMS.
Study NCT02919540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo care approach
Description: skin to skin contact between stable preterm infants and their naked mother's chest
Study NCT05513677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M4D
Description: Coated catheter
Study NCT05513677 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study NCT02341846 — intervention group
Intervention type: OTHER
Intervention: Qualitative interviews
Study NCT02070458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixazomib
Description: Given PO
Study NCT02070458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV
Study NCT02070458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT02070458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00443391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: Open label study, subjects will take up to 80mg daily for 24 months.
Study NCT02982161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MR308
Description: Over-encapsulated tablet, Dosing frequency: two times daily, Mode of administration: oral
Study NCT02982161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Over-encapsulated capsule, Dosing frequency: four times daily, Mode of administration: oral
Study NCT02982161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, Dosing frequency: four times daily, Mode of administration: oral
Study NCT02786537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EBR/GZR (elbasvir/grazoprevir)
Description: Elbasvir/grazoprevir (50/100mg) tablet once daily with or without food with or without RBV for 12 to 16 weeks
Study NCT02786537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 200 mg pills (1-3 pills, 1-2 times per day)
Study NCT01692587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein restrictive diet
Description: To begin a reduced protein diet
Study NCT01540734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed paracetamol
Description: Marketed formulation
Study NCT01540734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental paracetamol formulation
Description: Experimental formulation
Study NCT04508985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temporarily holding the RAAS inhibitor [intervention]
Description: Temporarily holding the RAAS inhibitor. Among participants who will be randomized to the intervention arm, a possible guideline-directed alternative to anti-hypertensive medication alternatives will be provided to the treating physician team.
Study NCT04508985 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: RAAS inhibitor [continued standard of care]
Description: No intervention, Continuation RAAS inhibitor \[continued standard of care\].
Study NCT00712049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: simvastatin 40 mg
Study NCT03738124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valiant Mona LSA Thoracic Stent Graft System
Description: The Valiant Mona LSA device is a modular two-component system consisting of a main stent graft (MSG) and a branch stent graft (BSG), delivered separately, designed to maintain LSA perfusion. Briefly, under general anesthesia and after heparin injection, a MSG access is achieved via a femoral artery. A Through-and-through wire access for delivery of the BSG is achieved via a brachial artery. After the placement of the main aortic stent graft in the arch with the cuff at the level of the ostium of the LSA, the BSG is placed through a femoral access.
Study NCT02598713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspiration Marker
Description: Instillation of Quinine suspended in sterile water in the retropharyngeal space of intubated ICU admitted patients for two consecutive days.
Study NCT05624372 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: hearing and cognitive assessment
Description: psychiatric assessment, hearing assessment and brief cognitive assessment
Study NCT00621023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine, Arsenic Trioxide and Ascorbic Acid
Description: Subjects receive decitabine 20 mg/m2 IV over one hour for days1-5 of each cycle, and arsenic trioxide 0.25 mg/kg IV for days 1-5 of cycle 1 followed by 0.25 mg/kg twice weekly (Mon-Thursday or Tues-Fri) for all remaining cycles. Patients will have transfusion and supportive care therapy administered per the treating physician's discretion. Patients with a response after 4 cycles of therapy may choose to continue on two more cycles of decitabine with arsenic and ascorbic acid given only during the first week of those two additional cycles.
Study NCT03440112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin (Not used as of 4/2020)
Description: Clarithromycin (generic) capsule 250mg each
Study NCT03440112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Not used as of 4/2020)
Description: Lactose in a gel capsule
Study NCT03440112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal flumazenil (Added 4/2020)
Description: Transdermal flumazenil 24mg/mL
Study NCT00712049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinic Acid
Description: daily dose starting with 500 mg, up to 2000mg
Study NCT01153503 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: Group Intraoperative (at the end of surgery): Ketorolac 30 mg, IV + TAP block; TAP block~First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h + IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn
Study NCT03440112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Added 4/2020)
Description: Transdermal placebo
Study NCT00676052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705 12.5mcg
Description: Once daily via dry powder inhaler
Study NCT00676052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705 25mcg
Description: once daily via dry powder inhaler
Study NCT00676052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705 50mcg
Description: Once daily via dry powder inhaler
Study NCT00676052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705 100mcg
Description: Once daily via dry powder inhaler
Study NCT00676052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705 200mcg
Description: Once daily via dry powder inhaler
Study NCT00676052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily via dry powder imhaler
Study NCT03600428 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Influenza Vaccine (LAIV)
Description: 1 dose, 0.2 mL, intranasal administration
Study NCT03600428 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Influenza Vaccine (IIV)
Description: 1 dose, 0.5 mL, intramuscular administration
Study NCT03004456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distraction
Description: Distraction will be provided by allowing the patient to will choose an age appropriate application (e.g. movie, game) which will be held for them during the blood draw.
Study NCT03429205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No external heating used during surgery
Description: Deviation from external heating for all surgery standard
Study NCT03429205 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: External heating blanket used during surgery
Description: Standard external heating plan used in all surgery types
Study NCT00661219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: BAY 38-9456 (vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.
Study NCT00661219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo will be matched for each vardenafil dosage form and will be indistinguishable from active treatment.
Study NCT04050748 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Achilles tendon repair
Description: Patients will be undergoing achilles tendon repair
Study NCT02361684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blended CBT treatment
Description: Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, (4) positive psychology, and (5) relapse prevention. These will be delivered over 10 sessions. For this study, the ratio between the number of face-to-face sessions and the number of online module will be 1/3 face-to-face and 2/3 online.
Study NCT02361684 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the primary care system. In practice, this means that treatment as usual may vary between patients. We will not interfere with treatment as usual but we will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report
Study NCT04050748 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Achilles tendon repair
Description: Patients will be undergoing achilles tendon repair
Study NCT03751787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cranial osteopathy
Description: two sessions at three weeks intervals
Study NCT03751787 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: comfort massage
Description: manipulation, comfort massage, standardized and not affecting the skull
Study NCT00267319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Study NCT03818932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Post-Operative Non Opioid Pain Protocol
Study NCT03818932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone-Acetaminophen
Description: Traditionally used narcotic pain protocol
Study NCT03818932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Post-Operative Non Opioid Pain Protocol
Study NCT03818932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Post-Operative Non Opioid Pain Protocol
Study NCT03818932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Post-Operative Non Opioid Pain Protocol
Study NCT03818932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: Post-Operative Non Opioid Pain Protocol
Study NCT01964456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measure of the heart rate
Study NCT04138966 — intervention group
Intervention type: DEVICE
Intervention: Nol-Index
Description: Multiparametric monitor that studies that establishes an index as a surrogate to nociception
Study NCT00829452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg capsule
Description: 1 x 10 mg
Study NCT00829452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Altace® 10 mg capsule
Description: 1 x 10 mg
Study NCT00849576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular Human Insulin
Description: 0.10 U/Kg- 15 minutes before ingestion of a standardized liquid meal.
Study NCT00849576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: 90% of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal.
Study NCT00849576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin VIAject™ (75%)
Description: 75 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
Study NCT00849576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin VIAject™ (90%)
Description: 90 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
Study NCT04211779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real tDCS
Description: Real tDCS (TCT Research Limited, Hong Kong); 3 times a week on alternate days for consecutive 6 weeks. The active session of tDCS will consist in applying anodal stimulation over left M1 (C3 according to the 10-20 international EEG placement) and the cathodal stimulation over right supraorbital area (Fp2 according to the 10-20 international EEG placement), and to inject 2 mA for 20 minutes through sponge electrodes (35 cm²) placed on the scalp.
Study NCT04211779 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham current (TCT Research Limited, Hong Kong); 3 times a week on alternate days for consecutive 6 weeks. The sham tDCS will use the same montage and device but direct current will only be injected for 30 seconds, with a ramp-up and ramp-down 15 seconds period, to mimic the somatosensory effects of active tDCS.
Study NCT04211779 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: The Exercise intervention will include only aerobic exercise 3 times a week on alternate days for consecutive 6 weeks. The program will last 20 minutes.
Study NCT04211779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The Exercise intervention will include only aerobic exercise 3 times a week on alternate days for consecutive 6 weeks. The program will last 20 minutes.
Study NCT04211779 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: The Exercise intervention will include only aerobic exercise 3 times a week on alternate days for consecutive 6 weeks. The program will last 20 minutes.
Study NCT01101620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Study NCT01101620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levosimendan
Study NCT02408367 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exercise
Description: 30 minutes endurance training at 75% of the Maximum heart rate
Study NCT02408367 — intervention group
Intervention type: BEHAVIORAL
Intervention: Relaxation
Description: 30
Study NCT00669721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: law molecular weigth heparin
Description: administration of LMWH as anticoagulation for hemodialysis circuit;nadroparin is administred ad the dosage of 65 IU/kg on starting dialysis and in the arterial hemodialytic line after a washing phase with 2 litres of a heparin-free saline solution 0.9%.
Study NCT00669721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: unfractioned heparin
Description: administration of UFH as anticoagulation of hemodialysis circuit; standard heparin ( Sodic Heparin, Vister by Parke-Davis) 1500 IU on starting dialysis and 1500 ± 500 IU in continues intradialytic infusion per dialysis session
Study NCT02312154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Vital
Description: stabilized hyaluronic acid (HA)-based gel of nonanimal origin
Study NCT02070783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARA290
Study NCT02070783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04919005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Environment
Description: The Virtual Environment was called SorrisoTur and consists of 10 mini-games with difficulty levels in a limited number of cities and mini-games distributed in a thematic scenario of the map of Brazil. The virtual environment consists of the cognitive training mini-games within a theme for all screens, mini-games, and information. The interventions with the Virtual Environment were administered in periods of one hour, twice a week, for a month.
Study NCT01438203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrust manipulation
Description: Thrust manipulation is a passive procedure which involves a high velocity low amplitude thrust to the spinal region
Study NCT01438203 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-thrust manipulation
Description: Non-thrust manipulation involves a low amplitude, low speed mobilization to the targeted region while adjusting the procedure based on patient feedback
Study NCT01571700 — intervention group
Intervention type: PROCEDURE
Intervention: Catheterization Pacing
Description: The second part of the study will include patients with pulmonary hypertension >5 who are scheduled for a cardiac catheterization for clinical reasons. We will at the conclusion of the routine catheterization, place two pacing catheters within the right atrium and right ventricle and pace the heart at a rate approximately 10% higher than sinus rhythm for 5 minutes. We will then measure dP/dT max in the ventricles, blood pressure and cardiac output using a Fick equation to assess hemodynamics. We will repeat this 3 times using different sites in the right ventricle while simultaneously obtaining echoes to assess mechanical synchrony.
Study NCT00245570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Montelukast
Description: 1 dose montelukast 10 mg tablet given orally in one of three treatment periods
Study NCT03187379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Exparel liposomal bupivacaine - 20cc Exparel® + 60cc Bupivicaine
Study NCT03187379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 60cc Bupivacaine
Study NCT01347164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RISE life coaching intervention
Description: 6 2-hour sessions
Study NCT01347164 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Counseling
Description: Standard one-hour HIV counseling session
Study NCT00245570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Salmeterol
Description: 1 dose of 50 ug salmeterol given by inhalation in one of three treatment periods
Study NCT00245570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo (montelukast)
Description: 1 dose matching-image placebo to montelukast tablet in two of three treatment periods
Study NCT00245570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo (salmeterol)
Description: 1 dose matching-image placebo of salmeterol 50 ug inhalation in two of three treatment periods
Study NCT04322045 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: multi-parametric MRI
Description: Multi-parametric MRI will be suggested for those PSA ≥4 ng/mL, PI-RADS v2 score will be used to evaluate images.
Study NCT01676350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IO access using EZ-IO®
Description: IO line placed using an FDA-approved device called an EZ-IO®.
Study NCT01991574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium acetate
Study NCT01991574 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron Hydroxide Adipate
Study NCT01991574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: methylcellulose capsules